ArticleACS catalysis2025
Divergent Enzymatic Synthesis of a Comprehensive Type‑1 Glycan Determinant Library.
Article in ACS catalysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glycoengineering strategies for constructing defined Mucin O-glycans.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Type-1 glycan unit, Galβ1-3GlcNAc, is one of the two major backbones from which the large glycan determinant repertoire is derived. Numerous type-1 glycan determinants, including Lewis-series antigens, have been identified, often featuring fucosylation and sialylation. In this study, we achieved efficient synthesis of 30 type-1 determinants using a divergent enzymatic strategy. The synthetic efficiency of eight fucosyltransferases (FucTs) was evaluated for the installation of fucose at every step of the type-1 determinant synthesis. Using selected FucTs and a few additional robust glycosyltransferases, 22 basic type-1 determinants were constructed at preparative scales in no more than three steps, starting from the type-1 unit. Additionally, 8 extended type-1 Lewis antigens were successfully synthesized in no more than five steps. Subsequent glycan microarray assays of these glycan determinants revealed intriguing recognitions by glycan-binding proteins and anti-type-1 Lewis antigen monoclonal antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.